Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease” Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...

Immuron sales surge by 66% in the Third Quarter of FY19 Key Highlights: Immuron achieved 66% YoY growth in worldwide sales for the third quarter of FY19, ending March 31, 2019.In Australia Q3 sales of Travelan® surged ahead, growing 73% YoY.In the US Q3...

Immuron Aims to Secure FDA Approval for IMM-124E to Prevent Travelers’ Diarrhea Key Points Immuron to develop U.S. registration dossier for IMM-124E for Travelers’ DiarrheaCompany anticipates significant inflection in sales with successful FDA registration of IMM-124ECompany to...